ArticleEuropean radiology2025
Can a low b-value diffusion-weighted imaging sequence replace the standard T2-weighted fluid-sensitive sequence in breast MRI? A single-center prospective study.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differentiation of hepatocellular carcinoma from hepatic hemangioma using diffusion-derived vessel density map-based radiomics features.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine whether a low b-value (b0) diffusion-weighted imaging (DWI) sequence of a similar acquisition time can fulfill the role of a T2-weighted/fluid-sensitive short tau inversion recovery (STIR) sequence. MATERIALS AND
methodsIn this prospective, single-institutional study, participants underwent 3-T or 1.5-T breast MRI, which included a standard T2-weighted/fluid-sensitive short TI inversion recovery (STIR) sequence and an investigational DWI sequence (comprising readout segmented echo planar imaging (rs-EPI) and simultaneous multi-slice (SMS) imaging). Five radiologists independently scored 121 lesions on imaging by answering three questions assessing lesion conspicuity, lesion signal characteristics, and artifact grading. Statistical analysis included one-sample tests of proportions and Nelson's model kappa.
resultsFrom 605 assessments in 72 patients (mean age, 48.3 ± 12.5 years [standard deviation]; 72 women), 537 (88.8%, p < 0.001) received assessments that lesion conspicuity on DWI was not inferior to STIR, 586 (96.9%, p < 0.001) received assessments that DWI followed the lesion signal characteristics on STIR, and 595 (98.3%, p < 0.001) received assessments that there were no or mild artifacts on DWI. Inter-reader agreement was substantial for similar lesion conspicuity (89.9%, к = 0.790, 95% CI: 0.76-0.82) and similar lesion signal characteristics (95.7%, к = 0.733, CI 0.69-0.77) on DWI and STIR, and moderate for whether there was mild/no artifact vs. moderate/substantial artifact on DWI (97.2%, к = 0.515, CI: 0.29-0.75).
conclusionLow b-value DWI provides similar diagnostic capabilities as T2-weighted/fluid-sensitive STIR, with comparable lesion conspicuity and lesion signal characteristics and without significant artifacts. KEY POINTS: Question Can diffusion-weighted imaging (DWI) be incorporated into clinical 1.5-T and 3-T breast MRI protocols without adding acquisition time? Findings The signal characteristics and conspicuity of breast lesions on low b-value (b0) DWI were not inferior compared with that on standard T2-weighted/fluid-sensitive imaging. Clinical relevance The incorporation of low b-value DWI can translate to improved cost-effectiveness and patient experience of breast MRI by reducing false-positives and reducing overall scan time.
Indexed as
Identifiers
40335657What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.